Guidelines for the next 10 years of proteomics

In the last ten years, the field of proteomics has expanded at a rapid rate. A range of exciting new technology has been developed and enthusiastically applied to an enormous variety of biological questions. However, the degree of stringency required in proteomic data generation and analysis appears to have been underestimated. As a result, there are likely to be numerous published findings that are of questionable quality, requiring further confirmation and/or validation. This manuscript outlines a number of key issues in proteomic research, including those associated with experimental design, differential display and biomarker discovery, protein identification and analytical incompleteness. In an effort to set a standard that reflects current thinking on the necessary and desirable characteristics of publishable manuscripts in the field, a minimal set of guidelines for proteomics research is then described. These guidelines will serve as a set of criteria which editors of PROTEOMICS will use for assessment of future submissions to the Journal.

💡 Research Summary

The manuscript provides a forward‑looking set of standards intended to shape proteomics research over the next decade. It begins by acknowledging the remarkable technological advances of the past ten years—high‑resolution mass spectrometers, data‑independent acquisition (DIA), single‑cell proteomics, and sophisticated labeling strategies—that have expanded the scope of biological inquiry. However, the authors argue that the rapid expansion has outpaced the community’s attention to methodological rigor, leading to a growing body of publications whose data quality is questionable.

The first major section addresses experimental design. The authors stress that statistical power calculations must be performed before sample collection, and that both biological and technical replicates should be incorporated in a randomized, blinded fashion. Quality‑control (QC) samples should be interspersed throughout runs to monitor instrument drift and to enable batch‑effect correction. Without these safeguards, systematic bias can masquerade as biological signal, compromising downstream interpretation.

The second section focuses on differential expression analysis and biomarker discovery. The manuscript warns against the common practice of reporting raw p‑values without correcting for multiple testing. It recommends a false‑discovery‑rate (FDR) threshold of ≤1 % as a baseline, and insists that any candidate biomarker be validated in an independent cohort. The authors discuss the trade‑offs among label‑free quantification, tandem mass tag (TMT), iTRAQ, and other multiplexed approaches, emphasizing that the chosen method’s limitations (e.g., ratio compression, channel cross‑talk) must be documented and experimentally verified.

In the third section, protein identification is examined. The authors require full disclosure of search engine(s), database version, mass tolerances, fixed and variable modifications, and any post‑search filtering steps. A protein should only be reported if it is identified by at least two unique peptides and the peptide‑level FDR is ≤1 %. The use of spectral libraries and orthogonal validation (e.g., targeted SRM/PRM) is encouraged to reduce false positives. Functional annotation (GO, KEGG, Reactome) should accompany the final protein list to aid biological interpretation.

The fourth section tackles analytical incompleteness. The authors note that a single LC‑MS/MS run typically captures only 60–80 % of the detectable proteome, making it essential to employ multiple technical replicates and diverse fractionation schemes (e.g., high‑pH reversed‑phase, strong‑cation exchange) to increase coverage. They advocate hybrid acquisition strategies that combine DIA’s breadth with DDA’s depth, thereby improving both detection sensitivity and quantitative accuracy.

Finally, the manuscript stresses data transparency and reproducibility. All raw files, search results, parameter files, and associated metadata must be deposited in public repositories such as PRIDE, MassIVE, or jPOST, following the MIAPE (Minimum Information About a Proteomics Experiment) guidelines. This open‑data policy enables other laboratories to re‑analyze the data, perform meta‑analyses, and verify the authors’ conclusions.

In conclusion, the paper proposes that the journal PROTEOMICS adopt these guidelines as part of its editorial policy. By enforcing rigorous experimental planning, robust statistical analysis, transparent reporting, and mandatory data sharing, the community can curb the proliferation of low‑quality studies and ensure that proteomics continues to deliver reliable, biologically meaningful insights that are ready for clinical translation and fundamental discovery.